Janux Therapeutics Stock Quote JANX - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

56.90

Bid

51.05

Ask

59.84

Volume

193

0.00 Day's Range 0.00

7.79 52 Week Range 71.71

Market Cap

2.986B

Previous Close

56.14

Open

Last Trade

56.14

Last Trade Time

04:56:11

Financial Volume

VWAP

Average Volume (3m)

992,328

Shares Outstanding

52,482,020

Dividend Yield

PE Ratio

-50.54

Earnings Per Share (EPS)

-1.11

Revenue

8.08M

Net Profit

-58.29M

Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer. Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.januxrx.com

Headquarters

Wilmington, Delaware, USA

Founded

Janux Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker JANX. The last closing price for Janux Therapeutics was $56.14. Over the last year, Janux Therapeutics shares have traded in a share price range of $ 7.79 to $ 71.71.

Janux Therapeutics currently has 52,482,020 shares outstanding. The market capitalization of Janux Therapeutics is $2.95 billion. Janux Therapeutics has a price to earnings ratio (PE ratio) of -50.54.

Form 4 - Statement of changes in beneficial ownership of securities

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its...

Form 4 - Statement of changes in beneficial ownership of securities

Form 424B5 - Prospectus [Rule 424(b)(5)]

Janux Therapeutics Announces Proposed Public Offering

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its...

Form 8-K - Current report

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Emerging JANX007 data demonstrated substantial clinical activity in 5L mCRPC patients, supporting clinical development plan directed at pre-PLUVICTO® 2L / 3L patients In 16 patients JANX007...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	2.35	4.30797433547	54.55	59.72	54.2	764526	56.70733982	CS
4	10.77	23.347062649	46.13	71.71	40.0183	1750609	59.70373427	CS
12	13.53	31.1966797325	43.37	71.71	40.0183	992328	55.62027153	CS
26	15.71	38.1403253217	41.19	71.71	34.5125	759068	50.89103543	CS
52	46.31	437.299338999	10.59	71.71	7.79	767433	48.14090043	CS
156	34.87	158.284157966	22.03	71.71	5.65	319571	41.18849137	CS
260	22.9	67.3529411765	34	71.71	5.65	300211	39.62917678	CS

JANX - Frequently Asked Questions (FAQ)

What is the current Janux Therapeutics share price?

The current share price of Janux Therapeutics is $ 56.90

How many Janux Therapeutics shares are in issue?

Janux Therapeutics has 52,482,020 shares in issue

What is the market cap of Janux Therapeutics?

The market capitalisation of Janux Therapeutics is USD 2.95B

What is the 1 year trading range for Janux Therapeutics share price?

Janux Therapeutics has traded in the range of $ 7.79 to $ 71.71 during the past year

What is the PE ratio of Janux Therapeutics?

The price to earnings ratio of Janux Therapeutics is -50.54

What is the cash to sales ratio of Janux Therapeutics?

The cash to sales ratio of Janux Therapeutics is 364.55

What is the reporting currency for Janux Therapeutics?

Janux Therapeutics reports financial results in USD

What is the latest annual turnover for Janux Therapeutics?

The latest annual turnover of Janux Therapeutics is USD 8.08M

What is the latest annual profit for Janux Therapeutics?

The latest annual profit of Janux Therapeutics is USD -58.29M

What is the registered address of Janux Therapeutics?

The registered address for Janux Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Janux Therapeutics website address?

The website address for Janux Therapeutics is www.januxrx.com

Which industry sector does Janux Therapeutics operate in?

Janux Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MGIHMillennium Group International Holdings Ltd	$ 4.65 (203.92%)	9.66M
ADDColor Star Technology Company Ltd	$ 4.20 (94.44%)	3.51M
TIRXTian Ruixiang Holdings Ltd	$ 2.80 (38.61%)	1.64M
LICNLichen China Limited	$ 0.2779 (32.27%)	14.24M
WAFUWah Fu Education Group Ltd	$ 2.26 (29.89%)	4.33M
NEUPNeuphoria Therapeutics Inc	4.25 (-35.90%)	31.07k
HOURHour Loop Inc	$ 2.87 (-34.77%)	214.11k
CREVCarbon Revolution Public Ltd	$ 6.66 (-27.29%)	29.53k
AVGRAvinger Inc	$ 1.06 (-26.90%)	380.48k
BAOSBaosheng Media Group Holdings Ltd	$ 5.26 (-25.92%)	60.73k
LICNLichen China Limited	$ 0.2779 (32.27%)	14.24M
MGIHMillennium Group International Holdings Ltd	$ 4.65 (203.92%)	9.66M
WAFUWah Fu Education Group Ltd	$ 2.26 (29.89%)	4.33M
LITMSnow Lake Resources Ltd	$ 0.667 (14.04%)	3.72M
ADDColor Star Technology Company Ltd	$ 4.20 (94.44%)	3.51M